Dasatinib, on the other hand, blocks several tyrosine kinases and promotes p21Cip1-dependent senescence by the induction of DNA damage in BRAF-mutant NSCLC cells [107,108]. This evidence concerns the gene CDKN1A and non-small cell lung carcinoma.